Thompson Siegel & Walmsley’s Humacyte HUMA Stock Holding History

Thompson Siegel & Walmsley’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-160,300	Closed	-$335K	–	420
2025 Q2	$335K	Buy	+160,300	New	+$308K	0.01%	365

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Thompson Siegel & Walmsley's HUMA Position: Q3 2025 in Review

Thompson Siegel & Walmsley sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 92,000 shares — an estimated $192K sold.

Thompson Siegel & Walmsley first reported a position in HUMA in Q4 2024 and held it in 3 quarters. The position peaked at $192K in Q2 2025. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

Thompson Siegel & Walmsley reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
Thompson Siegel & Walmsley sold 92,000 Humacyte shares in Q3 2025, an estimated $192K.
Thompson Siegel & Walmsley first reported a position in Humacyte in Q4 2024 and held it in 3 quarters.
Thompson Siegel & Walmsley's Humacyte position peaked at $192K in Q2 2025.
141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on Thompson Siegel & Walmsley's 13F filing for Q3 2025, filed 12 Nov 2025.